A Phase 1, Single Site, Open-Label Study to Assess the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Pegloticase (KRYSTEXXA) in Patients on Hemodialysis
Phase of Trial: Phase I
Latest Information Update: 27 Mar 2015
At a glance
- Drugs Pegloticase (Primary)
- Indications Gout
- Focus Pharmacokinetics
- Sponsors Savient Pharmaceuticals
- 08 Oct 2013 Data will be presented at the American Society of Nephrology (ASN) Kidney Week 2013, according to a Savient Pharmaceuticals media release.
- 03 Oct 2013 Results will be presented at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2013 Annual Meeting according to a Savient Pharmaceuticals media release.
- 19 Mar 2013 Status changed from recruiting to completed, as reported in a Savient Pharmaceuticals media release.